It's now a new ballgame for CRISPR Therapeutics (NASDAQ: CRSP). The company, along with its big partner, Vertex Pharmaceuticals (NASDAQ: VRTX), won U.S. regulatory approval for Casgevy (exa-cel) in treating sickle cell disease (SCD) on Dec. 8, 2023. Casgevy picked up U.K. approval for SCD and transfusion-dependent beta thalassemia last month.

Despite the milestone U.S. approval, CRISPR Therapeutics stock sank nearly 19% after the Food and Drug Administration (FDA) made its decision. Shares have rebounded somewhat but remain close to 15% below the previous high.

We could be seeing a textbook case of "buy the rumor, sell the news" with CRISPR Therapeutics. But here's the one key reason why you might want to buy the gene-editing stock on the dip.

Continue reading

Source Fool.com